Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 2, 2007 Brian Lawler	Progenics Submits for Its Future Progenics submits a New Drug Application for its lead compound. Whether the sales and royalty revenue that methylnaltrexone can bring in will be enough to support its current valuation is still in doubt.
The Motley Fool March 9, 2007 Brian Lawler	Progenics Gets Backed Up Progenics Pharmaceutics and drugmaker giant Wyeth announced a delay in one of their methylnaltrexone programs. Investors, take note.
The Motley Fool June 4, 2007 Brian Lawler	Progenics Is on the Clock The biotech's marketing application for its lead compound gets accepted for review. Investors, take note.
The Motley Fool October 15, 2009 Brian Orelli	This Partnership Will Go No Further Wyeth and Progenics call it quits.
The Motley Fool March 13, 2008 Brian Orelli	Progenics Down but Not Out Progenics Pharmaceuticals' drug to help patients after abdominal surgery fails in its phase 3 trial. Investors, take note.
The Motley Fool September 13, 2007 Brian Orelli	Progenics Progresses Progenics and partner Wyeth announce plans to start three new clinical trials on their constipation-relieving drug. The patient treatment time for the trials is relatively short, so investors won't have to wait too long to see how the drug performs.
The Motley Fool April 25, 2008 Brian Orelli	Progenics' Double Dose of Good News Its lead drug gets FDA approval and a positive EU recommendation.
The Motley Fool May 23, 2008 Brian Orelli	Progenics' Mixed Trial Data Progenics Pharmaceuticals and marketing partner Wyeth release both positive and negative clinical trial data.
The Motley Fool July 10, 2007 Brian Lawler	Adolor Tries Again Adolor continues work on its second drug candidate. Investors will have to wait until early 2008 for some data to sink their teeth into.
The Motley Fool November 28, 2008 Brian Orelli	Will Patients Reject This Injection? Wyeth and Progenics release good trial data, but will patients want their constipation drug?
The Motley Fool September 22, 2009 Brian Orelli	Nektar Tastes Sweet Nektar is getting an up-front payment of $125 million and AstraZeneca is taking over development of two of its compounds.
The Motley Fool September 14, 2007 Brian Lawler	FDA Keeps Adolor Waiting Adolor and partner GlaxoSmithKline continue playing the FDA waiting game, as the agency has still not decided whether to allow clinical trials of Adolor's top drug to continue.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool September 5, 2006 Brian Lawler	Adolor: Positive Results, Negative Reaction The market seems confused by good results from Adolor's latest clinical trial. Investors willing to take a gamble on Adolor at this price may be in for huge rewards if the company and Glaxo can convince the FDA of Entereg's viability.
The Motley Fool November 27, 2007 Brian Lawler	Cardiome Makes Them Wait Cardiome Pharma announces a delay in the release of data on an oral version of its lead heart drug. Investors, take note.
The Motley Fool January 22, 2008 Brian Lawler	Adolor Under the FDA's Spotlight The FDA releases its documents on Adolor's lead drug, with surprising good news in advance of an advisory panel discussion. Investors, take note.
The Motley Fool August 29, 2007 Brian Lawler	Adolor Stays in the Ring Adolor takes another run at getting FDA approval for its lead drug. Shares of the biotech firm are up on news the FDA had accepted for review additional information about its ileus medication, Entereg.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool January 20, 2004 David Nierengarten	Adolor's Knocked-Out Drug The biotech's stock is pummeled after mixed-up trial results.
The Motley Fool May 22, 2007 Brian Lawler	Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool April 11, 2007 Brian Lawler	Adolor: Down and Out? The drug developer announces dour clinical trial results. Shares of Adolor crashed nearly 60% on the news.
The Motley Fool January 24, 2008 Brian Lawler	Adolor Advisory Panel Aftermath An FDA advisory panel votes favorably on Adolor's lead drug.
The Motley Fool April 29, 2011 Brian Orelli	Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.
The Motley Fool December 20, 2011 Brian D. Pacampara	Salix Pharmaceuticals Shares Popped: What You Need to Know Shares of drugmaker Salix Pharmaceuticals climbed as high as 10.5% on Tuesday after the company reported positive phase-3 data for an oral version of its constipation treatment, Relistor.
The Motley Fool June 12, 2007 Brian Lawler	Adolor Is Still Swinging The drugmaker bumps into the FDA as it pushes to do more testing of Entereg.
The Motley Fool November 30, 2007 Brian Lawler	FDA Throws Adolor a Bone Pharmaceutical company Adolor gets an advisory panel hearing on its lead drug. Investors, take note.
The Motley Fool April 23, 2008 Brian Orelli	Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool July 27, 2010 Jim Mueller	3 Stocks to Play Biotech Here are three promising ideas for this exciting area.
The Motley Fool April 29, 2008 Brian Orelli	Will These Drugs Get FDA Approval? Discovery Laboratories and Adolor are waiting FDA decisions on their drugs next month.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
The Motley Fool June 8, 2010 Brian Orelli	Injecting Uncertainty Into the Multiple Sclerosis Market Novartis' oral MS drug could be a blockbuster -- if it can get past the FDA.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool May 30, 2008 Brian Orelli	No Love for Antibiotics From the FDA Wyeth gets an approvable letter for its antibiotic Tygacil.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool March 15, 2007 Brian Lawler	Adolor's New Plan Adolor updates investors on its plans for its lead drug program.
The Motley Fool May 1, 2007 Brian Lawler	Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note.
The Motley Fool August 24, 2011 Brian D. Pacampara	United Therapeutics Shares Got Crushed: What You Need to Know Shares of drugmaker United Therapeutics plunged 17% today after its experimental orally administered lung drug failed in a late-stage clinical trial.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool July 20, 2007 Billy Fisher	Wyeth Keeps Working Its Magic The drugmaker's second-quarter boasts 12% earnings growth. Of particular promise was the reversal over first-quarter for its top seller, the antidepressant Effexor.
The Motley Fool November 8, 2006 Brian Lawler	Stumbling Block for Adolor Another approvable letter from the FDA means investors may have to be patient.
The Motley Fool August 23, 2006 S.J. Caplan	Wyeth Feeling Happy The FDA cancels a meeting related to the market application for Wyeth's experimental antidepressant. Investors, take note.
The Motley Fool September 24, 2009 Brian Orelli	Wyeth's Biting the Hand That Feeds It Wyeth decides to sue the Food and Drug Administration after it approved Orchid Chemicals & Pharmaceuticals' generic version of its antibiotic Zosyn.
Pharmaceutical Executive October 1, 2006 Clinton & Koroneos	Learn & Confirm At Wyeth, a sweeping set of initiatives is transforming the R&D operation - and spotlighting a possible future for drug development.
The Motley Fool May 1, 2007 Mike Havrilla	Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.